An Injectable Puerarin Depot Can Potentiate Chimeric Antigen Receptor Natural Killer Cell Immunotherapy Against Targeted Solid Tumors by Reversing Tumor Immunosuppression
Small · 2024
DOI: 10.1002/smll.202307521 ↗Kurz gefasst
Fachartikel in der Zeitschrift Small, 2024. Verfasst von Yan Liu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Jiangsu Key Laboratory for Molecular and Medical Biotechnology, Cancer Institute, Department of Biochemistry, College of Life Science, Nanjing Normal…. Hauptthemen laut MEDLINE: Killer Cells, Natural, Isoflavones, Receptors, Chimeric Antigen, Immunotherapy. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 36 Literaturangaben. Gefördert von: National Natural Science Foundation of China, National Research Programs from Ministry of Science and Technology (MOST) of China, Basic Science (Natural Science) Research Projects in Higher Education Institutions in Jiangsu Province.
Abstract (Originalsprache)
Chimeric antigen receptor natural killer (CAR‐NK) cell therapy represents a potent approach to suppressing tumor growth because it has simultaneously inherited the specificity of CAR and the intrinsic generality of NK cells in recognizing cancer cells. However, its therapeutic potency against solid tumors is still restricted by insufficient tumor infiltration, immunosuppressive tumor microenvironments, and many other biological barriers. Motivated by the high potency of puerarin, a traditional Chinese medicine extract, in dilating tumor blood vessels, an injectable puerarin depot based on a hydrogen peroxide‐responsive hydrogel comprising poly(ethylene glycol) dimethacrylate and ferrous chloride is concisely developed. Upon intratumoral fixation, the as‐prepared puerarin depot (abbreviated as puerarin@PEGel) can activate nitrogen oxide production inside endothelial cells and thus dilate tumor blood vessels to relieve tumor hypoxia and reverse tumor immunosuppression. Such treatment can thus promote tumor infiltration, survival, and effector functions of customized epidermal growth factor receptor (HER1)‐targeted HER1‐CAR‐NK cells after intravenous administration. Consequently, such puerarin@PEGel‐assisted HER1‐CAR‐NK cell treatment exhibits superior tumor suppression efficacy toward both HER1‐overexpressing MDA‐MB‐468 and NCI‐H23 human tumor xenografts in mice without inducing obvious side effects. This study highlights a potent strategy to activate CAR‐NK cells for augmented treatment of targeted solid tumors through reprogramming tumor immunosuppression.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Jiangsu Key Laboratory for Molecular and Medical Biotechnology, Cancer Institute, Department of Biochemistry, College of Life Science, Nanjing Normal University, Nanjing, 210023, P. R. China.
- Institute of Functional Nano & Soft Materials (FUNSOM), Jiangsu Key Laboratory for Carbon-Based Functional Materials & Devices, Soochow University, 199 Ren'ai Road, Suzhou, 215123, P. R. China.
- Department of Radiology, The First Affiliated Hospital of Soochow University, Suzhou, 215006, P. R. China.
- Department of General Surgery, The First Affiliated Hospital of Soochow University, Suzhou, 215000, P. R. China.
ORCID-Profile: Yan Liu, Liangzhu Feng
Förderung
- National Natural Science Foundation of China
- National Research Programs from Ministry of Science and Technology (MOST) of China
- Basic Science (Natural Science) Research Projects in Higher Education Institutions in Jiangsu Province
- Natural Science Foundation of Jiangsu Province
- Suzhou Key Laboratory of Nanotechnology and Biomedicine
- Collaborative Innovation Center of Suzhou Nano Science and Technology
- 111 Program from the Ministry of Education of China
Zitieren
APA
Liu, Y., Hao, Y., Chen, J., Chen, M., Tian, J., Lv, X., Zhang, Y., Ma, X., Zhou, Y., & Feng, L. (2024). An Injectable Puerarin Depot Can Potentiate Chimeric Antigen Receptor Natural Killer Cell Immunotherapy Against Targeted Solid Tumors by Reversing Tumor Immunosuppression. Small. https://doi.org/10.1002/smll.202307521
Vancouver
Liu Y, Hao Y, Chen J, Chen M, Tian J, Lv X, et al. An Injectable Puerarin Depot Can Potentiate Chimeric Antigen Receptor Natural Killer Cell Immunotherapy Against Targeted Solid Tumors by Reversing Tumor Immunosuppression. Small. 2024. doi:10.1002/smll.202307521
BibTeX
@article{Liu2024,
author = {Liu, Yan and Hao, Yu and Chen, Jiahui and Chen, Minming and Tian, Jia and Lv, Xiang and Zhang, Yefei and Ma, Xinxing and Zhou, Yehui and Feng, Liangzhu},
title = {An Injectable Puerarin Depot Can Potentiate Chimeric Antigen Receptor Natural Killer Cell Immunotherapy Against Targeted Solid Tumors by Reversing Tumor Immunosuppression},
journal = {Small},
year = {2024},
doi = {10.1002/smll.202307521}
}
EUVIMED